Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel , Nov. 7, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company
CARMIEL, Israel , Sept. 6, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercializati
Protalix BioTherapeutics Inc. (NYSE:PLX ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Chuck Padala - LifeSci Advisors, Investor Relations Dror Bashan - President,
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , Aug. 8, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical compan
Protalix BioTherapeutics Inc. (NYSE:PLX ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Alexandra Schuman - LifeSci Advisors, IR Dror Bashan - President & CEO Eyal Rubi
Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., have announced topline data from the BALANCE Phase 3 trial evaluating pegunigalsida
Protalix BioTherapeutics (PLX) CEO, Dror Bashan on Q4 2021 Results - Earnings Call Transcript
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, March 24, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE:  PLX), a biopharmaceutical co
Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A, have announced final results from the BRIGHT Phase 3 trial of pegunigalsidase alfa (P
Protalix BioTherapeutics (PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., submitted an application via centralized procedure to the European Medicines…

Protalix Biotherapeutics: Is It Worth The Wait?

01:30pm, Friday, 07'th Jan 2022 Seeking Alpha
Protalix concluded its Type A meeting with the US Food and Drug Administration (FDA), providing a way forward with its lead indication PRX-102. Protalix published top line results of the interim analy
PolarityTE, Inc. (NASDAQ:PTE) with the stream of 1.65% also noticed, India Protalix BioTherapeutics, Inc. (AMEX:PLX) encountered a rapid change of 5.26% in the last hour of Thursdays trading session. PolarityTE, The post Have an attention on: PolarityTE, Inc. (NASDAQ:PTE), Protalix BioTherapeutics, Inc. (AMEX:PLX) appeared first on Stocks Equity .
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE